Moderna (NASDAQ:MRNA) PT Raised to $77.00 at SVB Leerink

Moderna (NASDAQ:MRNAGet Rating) had its price objective upped by stock analysts at SVB Leerink from $70.00 to $77.00 in a research report issued on Monday, MarketBeat reports. The brokerage currently has an “underperform” rating on the stock. SVB Leerink’s price objective suggests a potential downside of 52.12% from the stock’s current price.

A number of other equities analysts have also weighed in on the stock. Piper Sandler cut their target price on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a research report on Tuesday, May 17th. Morgan Stanley increased their target price on shares of Moderna from $205.00 to $217.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $228.58.

Moderna Stock Performance

NASDAQ MRNA opened at $160.81 on Monday. Moderna has a 52-week low of $115.61 and a 52-week high of $497.49. The company has a 50-day simple moving average of $149.27 and a 200 day simple moving average of $152.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.77. The company has a market capitalization of $63.96 billion, a PE ratio of 4.73, a price-to-earnings-growth ratio of 0.93 and a beta of 1.61.

Moderna (NASDAQ:MRNAGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported $8.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.18 by $3.40. The firm had revenue of $6.07 billion during the quarter, compared to analyst estimates of $4.43 billion. Moderna had a net margin of 64.77% and a return on equity of 121.86%. The company’s quarterly revenue was up 213.2% on a year-over-year basis. During the same quarter last year, the business earned $2.84 earnings per share. On average, research analysts predict that Moderna will post 27.17 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 234 shares of Moderna stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total transaction of $31,288.14. Following the completion of the sale, the president now directly owns 1,622,820 shares in the company, valued at $216,987,262.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Moderna news, insider Juan Andres sold 195 shares of Moderna stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total transaction of $26,073.45. Following the transaction, the insider now directly owns 9,309 shares of the company’s stock, valued at $1,244,706.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Stephen Hoge sold 234 shares of Moderna stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $133.71, for a total transaction of $31,288.14. Following the transaction, the president now directly owns 1,622,820 shares in the company, valued at $216,987,262.20. The disclosure for this sale can be found here. Insiders sold a total of 554,029 shares of company stock worth $82,263,545 over the last three months. 17.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Field & Main Bank purchased a new position in shares of Moderna during the fourth quarter worth approximately $25,000. Confluence Wealth Services Inc. purchased a new position in shares of Moderna in the fourth quarter worth $25,000. Standard Family Office LLC purchased a new position in shares of Moderna in the fourth quarter worth $25,000. Total Clarity Wealth Management Inc. purchased a new position in shares of Moderna in the second quarter worth $25,000. Finally, AllSquare Wealth Management LLC purchased a new position in shares of Moderna in the first quarter worth $26,000. 61.20% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Want More Great Investing Ideas?

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.